Compare RETO & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RETO | SCNI |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.9M |
| IPO Year | 2017 | N/A |
| Metric | RETO | SCNI |
|---|---|---|
| Price | $1.09 | $0.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 323.3K | 53.7K |
| Earning Date | 10-17-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $2,109,956.00 | $1,147,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.82 |
| Revenue Growth | ★ 16864.81 | 303.87 |
| 52 Week Low | $0.83 | $0.61 |
| 52 Week High | $61.50 | $6.18 |
| Indicator | RETO | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 34.22 | 36.30 |
| Support Level | $0.88 | $0.75 |
| Resistance Level | $1.45 | $0.86 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 13.98 | 0.00 |
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Machinery and Equipment sales, and Technology Consulting and other services. The company earns its revenue from the Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.